Core Insights - The company reported a significant increase in revenue and net profit for the third quarter of 2025, indicating strong financial performance driven by overseas sales and cost management efforts [1] Financial Performance - The company's total revenue for the first three quarters reached 1.15 billion yuan, a year-on-year increase of 10.5% [1] - The net profit attributable to shareholders was 111 million yuan, up 547.7% year-on-year [1] - The net profit excluding non-recurring items was 70.45 million yuan, reflecting a year-on-year increase of 190.6% [1] - The operating cash flow showed a net outflow of 7.26 million yuan, a decline of 113.6% compared to the previous year [1] - The earnings per share (EPS) on a fully diluted basis was 0.5528 yuan [1] Quarterly Highlights - In the third quarter alone, the company achieved revenue of 447 million yuan, marking a substantial year-on-year increase of 60.6% [1] - The net profit for the third quarter was 30.92 million yuan, which is an increase of 483.3% year-on-year [1] - The net profit excluding non-recurring items for the third quarter was 25.17 million yuan, showing an impressive year-on-year growth of 829.5% [1] - The EPS for the third quarter was reported at 0.1536 yuan [1] Growth Drivers - The significant growth in net profit for the year-to-date period is attributed to increased sales in the EU market, which boosted overseas revenue [1] - The company has been actively managing costs in the marketing sector, leading to a reduction in sales expenses [1] - Non-recurring gains from the disposal of subsidiaries and changes in the fair value of private equity funds contributed to the increase in net profit [1]

Group 1 - Key Point 1: As of October 29, 2025, a total of 12 institutional investors hold shares in Kexing Pharmaceutical (688136.SH), with a combined holding of 119 million shares, representing 59.24% of the total share capital [1] - Key Point 2: The top ten institutional investors account for a combined holding ratio of 59.23%, with a decrease of 13.28 percentage points compared to the previous quarter [1] Group 2 - Key Point 1: In the current period, four public funds increased their holdings, accounting for an increase of 0.21% [2] - Key Point 2: Two public funds reduced their holdings, with a decrease of 1.33% compared to the previous quarter [2] - Key Point 3: Three new public funds were disclosed in the current period, while 156 public funds were not disclosed in the current quarter [2]

Core Viewpoint - The company emphasizes the accuracy and completeness of its quarterly report, ensuring no false statements or omissions exist, and holds legal responsibility for the report's content [2][3]. Financial Data - The financial statements for the third quarter are unaudited, covering the period from the beginning to the end of the quarter [3][6]. - The report includes major accounting data and financial indicators, but specific figures are not provided in the text [3][6]. - The company reported no net profit from mergers under common control for the current and previous periods [6]. Shareholder Information - The total number of ordinary shareholders and the top ten shareholders' holdings are disclosed, with "Kexing Biological Pharmaceutical Co., Ltd. Repurchase Special Securities Account" holding 3,149,905 shares, representing 1.57% of the total [4][6]. Other Important Information - There are no significant changes in the shareholding structure or other operational reminders for the reporting period [5][6].

Group 1 - The core viewpoint of the article highlights the financial performance of Kexing Pharmaceutical in Q3 2025, showing significant growth in revenue and net profit [1] - Kexing Pharmaceutical reported a revenue of approximately 1.148 billion yuan for the first three quarters, representing a year-on-year increase of 10.54% [1] - The net profit attributable to shareholders was approximately 111 million yuan, reflecting a substantial year-on-year increase of 547.7% [1] - Basic earnings per share reached 0.56 yuan, marking a year-on-year increase of 522.22% [1] Group 2 - As of the report, Kexing Pharmaceutical has a market capitalization of 7.7 billion yuan [2]

Core Insights - The company reported a significant increase in revenue and net profit for the first three quarters of 2025, with a revenue of 1.148 billion and a net profit of 111 million, reflecting year-on-year growth of 10.54% and 547.7% respectively [1] - In Q3 alone, the company achieved a revenue of 447 million, marking a substantial year-on-year increase of 60.65% and a quarter-on-quarter increase of 28.9% [1] - The company is focusing on research and development innovation, with multiple breakthroughs in its core pipeline and enhanced R&D efficiency through diverse collaborations [1] Group 1: R&D and Product Development - The company has made progress in the oncology field with the GB18 project, a GDF-15 targeted monoclonal antibody, which has entered clinical phase I after receiving approvals from both the FDA and NMPA [1] - Another innovative drug, GB10, aimed at treating retinal neovascular diseases, has had its clinical trial application accepted by the NMPA [1] - The company is expanding its pipeline in the immunology field, targeting large patient populations with conditions such as atopic dermatitis and inflammatory bowel disease [2] Group 2: Strategic Collaborations and Internationalization - The company is actively collaborating with renowned domestic and international institutions, enhancing its R&D efforts on a global scale [3] - It has established a joint initiative for the overseas expansion of the pharmaceutical and medical device industry, providing comprehensive services for international market entry [3] - The company has signed multiple overseas commercialization agreements focusing on major disease areas such as oncology, immunology, orthopedics, and ophthalmology, securing international market collaboration rights for several key products [3]

证券代码：688136 证券简称：科兴制药 公告编号：2025-089 科兴生物制药股份有限公司 自愿披露关于 GB18 注射液 I 期临床试验完成首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，科兴生物制药股份有限公司（以下简称"公司"）全资子公司深圳科 兴药业有限公司（以下简称"深圳科兴"）研发的"GB18注射液"I期临床研究 成功完成首例受试者入组给药。 公司子公司深圳科兴于 2025 年 5 月获得国家药品监督管理局（以下简称"国 家药监局"）签发的《药物临床试验批准通知书》（受理号：CXSL2500226）， 国家药监局同意深圳科兴 GB18 注射液按照提交的方案开展肿瘤恶病质的临床 试验。 1 公司 GB18 注射液正在开展随机、双盲、安慰剂对照的Ⅰ期临床研究，旨在 评估 GB18 注射液在健康参与者中单次皮下给药和肿瘤恶病质患者中多次皮下 给药的安全性、耐受性、药代动力学、药效学特征以及在肿瘤恶病质患者中初步 有效性，于近日成功完成首例受试者入组给药。 此外，公司 GB18 注射液 ...

第三季度财务报表是否经审计 □是 √否 一、主要财务数据 科兴生物制药股份有限公司 2025 年第三季度报告 证券代码：688136 证券简称：科兴制药 科兴生物制药股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 期末比上年 | | | | 减变动幅度 | | 同期增减变 | | | | (%) | | 动幅度(%) | | 营业收入 | 447,174,374.72 | 60.65 | 1,147, ...

科兴制药公告，全资子公司深圳科兴药业有限公司研发的"GB18注射液"I期临床研究成功完成首例受试 者入组给药。 ...

Core Viewpoint - The company is focusing on international market opportunities for its pharmaceuticals, particularly through a collaboration with Sinovac Biotech for the commercialization of Anglatavir tablets in Macau [1] Group 1: International Expansion - The company has established a commercial partnership with Sinovac Biotech for Anglatavir tablets in Macau, aiming to leverage regional presence for brand expansion [1] - The company plans to explore further international market opportunities and accelerate its globalization efforts [1] Group 2: Market Monitoring and Production - The company is closely monitoring disease dynamics to ensure effective production and sales of its pharmaceuticals [1]

Core Viewpoint - The company is focusing on international market opportunities for its pharmaceuticals, specifically through a collaboration with Sinovac Biotech for the commercialization of Anglatavir tablets in Macau, which aims to enhance its brand presence overseas and support its international expansion efforts [1] Group 1 - The company has established a commercial partnership with Sinovac Biotech for Anglatavir tablets in Macau [1] - This collaboration is intended to create a brand radiating effect in international markets [1] - The company plans to explore further international market opportunities and accelerate its globalization efforts [1] Group 2 - The company is closely monitoring disease dynamics and is committed to effective drug production and sales [1]